See also Antiviral Drugs. Action/Kinetics: HIV-1 protease inhibitor which results in the production of immature, non-infectious viruses. Activity is increased when used with didanosine, lamivudine, stavudine, zalcitabine, or zidovu-dine. Peak plasma levels: 2-4 hr. Steady-state plasma levels: 3-4 mcg/mL. Food increases plasma levels 2-3 fold. tvi, terminal: 3.5-5 hr. Metabolites (one of which is as active as parent compound) and unchanged drug excreted mainly in feces.
Uses: Treat HIV infection when anti-retroviral therapy is required. Contraindications: Administration with astemizole, cisapride, midazo-lam, rifampin, terfenadine, or triazo-lam. Hypersensitivity. Special Concerns: Use with caution with hepatic impairment. Safety and efficacy have not been determined in children less than 2 years of age.
Side Effects: Side effects were determined when used in combination with other antiviral drugs. Oral: Mouth ulcers. GI: N&V, diarrhea, flatulence, abdominal pain, anorexia, dyspepsia, epigastric pain, GI bleeding, hepatitis, pancreatitis. CNS: Anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paresthesia, seizures, sleep disorder, somnolence, suicide ideation. Hematologic: Anemia, leukope-nia, thrombocytopenia. Respiratory: Dyspnea, rhinitis, sinusitis, pharyngitis. GU: Kidney calculus, sexual dysfunction, urine abnormality. Ophthalmic: Eye disorder, acute ir itis. Musculoskeletal: Arthralgia, arthritis, cramps, myalgia, myasthenia, myopathy. Dermatologic: Dermatitis, folliculitis, fungal dermatitis, macu-lopapular rash, pruritus, urticaria, sweating. Miscellaneous: Asthenia, dehydration, allergic reaction, back pain, fever, headache, malaise, pain, accidental injury.
Drug Interactions Anticonvulsants / Possible l plasma levels of nelfinavir Astemizole / Potential for serious and life-threatening cardiac arrhythmias
Terfenadine / Potential for serious and life-threatening cardiac arrhythmias
Was this article helpful?